Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

@article{Diener2004AspirinAC,
  title={Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial},
  author={Hans Christoph Diener and Julien Bogousslavsky and Lawrence M. Brass and Claudio Cimminiello and L{\'a}szl{\'o} Csiba and Markku Kaste and Didier Leys and Jordi A. Matias‐Guiu and Hans J. Rupprecht},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={331-337}
}

Figures and Tables from this paper

Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial
  • G. Hankey, S. Johnston, E. Topol
  • Medicine
    International journal of stroke : official journal of the International Stroke Society
  • 2011
TLDR
The data are consistent with, but do not prove the hypothesis that early addition of clopidogrel to acetylsalicylic acid in patients with transient ischaemic attack and ischaemia stroke of arterial origin may be more effective and acceptably safe compared with acetyl salicylic Acid alone.
Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
TLDR
The use of three antiplatelet agents is associated with increased bleeding without any significant reduction in recurrence of stroke or TIA, and the trial was stopped early, thereby reducing its statistical power.
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs – is antiplatelet monotherapy still reasonable?
TLDR
Early treatment with aspirin in patients with acute ischaemic stroke was investigated in two large clinical trials and resulted in a reduction of 10 deaths or recurrent strokes and causes two haemorrhagic strokes per 1000 treated patients.
Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial
TLDR
Combination therapy with aspirin added to clopidogrel has had a disappointing record in the prevention of recurrent stroke, but was associated with two to three times the risk of major or life-threatening haemorrhage in one study, and major haemsorrhages were increased by almost double in the other study.
A Randomised Controlled Trial of Triple Antiplatelet Therapy (Aspirin, Clopidogrel and Dipyridamole) in the Secondary Prevention of Stroke: Safety, Tolerability and Feasibility
TLDR
Long term triple antiplatelet therapy was asociated with a significant increase in adverse events and bleeding rates, and their severity, and a trend to increased discontinuations, however, the patients had a low risk of recurrence and future trials should focus on short term therapy in high risk patients characterised by a very recent event or failure of dual antiplatelets therapy.
Safety of Clopidogrel and Aspirin for Stroke Prevention
TLDR
The results of the CHARISMA trial support this recommendation; despite previous data demonstrating a favourable benefit-risk profile of aspirin plus clopidogrel in patients with acute coronary syndrome, this combination should not be used in patients at high risk for atherothrombosis and those with previous stroke or TIA.
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes
TLDR
The early benefit of clopidogrel-aspirin treatment in reducing the risk of subsequent stroke persisted for the duration of 1-year of follow-up.
...
...

References

SHOWING 1-10 OF 28 REFERENCES
Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data
TLDR
MATCH is a major ongoing trial that will provide important data on the benefit of clopidogrel and ASA compared with clopIDogrel alone for reduction of vascular ischaemic events in patients with recent TIA or IS who are at high risk of atherothrombotic event recurrence.
A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
TLDR
Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
TLDR
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
TLDR
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TLDR
Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TLDR
Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Comparative Safety and Tolerability of Clopidogrel and Aspirin
TLDR
Given the favourable benefit/risk ratio, clopidogrel represents a clinically important advance in the treatment of patients with manifest atherosclerotic disease.
Ongoing and Planned Trials of Antiplatelet Therapy in the Acute and Long-Term Management of Patients with Ischaemic Brain Syndromes: Setting a New Standard of Care
  • G. Hankey
  • Medicine
    Cerebrovascular Diseases
  • 2004
TLDR
The greater efficacy of the combinations of ASA with clopidogrel, and ASA with an intravenously administered GP IIb/IIIa receptor antagonist, in patients with ACS and those undergoing PCI has fostered several ongoing and planned trials of these regimens in the acute and long-term management of patients with ischaemic brain syndromes.
Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events
TLDR
The absolute benefit of clopidogrel over ASA seemed to be amplified in high-risk patients, and patients with a history of prior symptomatic atherosclerotic disease had a high rate of subsequent ischemic events.
...
...